Table 3.
Efficacy of ICIs in NSCLS with c-MET mutations.
| Reference | Characteristics | ORR, % | mPFS, months | mOS, months since start of ICI |
|---|---|---|---|---|
| Sabari JK. et al. (12) | cMET exon 14 skipping mutation (n=147) | 17 | 1.9 | 18.2 |
| Mazieres J., et al. (31) | cMET exon 14 skipping mutation and cMET amplification (n=36) | 49 | 3.4 | 18.4 |
| Guisier F., et al. (47) | cMET mutant (n=30) | 36 | 4.9 | 13.4 |
| Dudnik- E., et al. (46) | cMET exon 14 skipping mutation (n=148) | 12 | 4 | NR (not reached) |
| cMET amplification (n=54) | 25 | 4.9 | NR (not reached) | |
| Mayenga M., et al. (56) | cMET exon 14 skipping mutations, 2nd line immunotherapy (n=13) | 46.2 |
ICIs, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; ORR, overall response rate; mPFS, median progression-free survival; mOS, median overall survival.